Clinical Research Directory
Browse clinical research sites, groups, and studies.
Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer
Sponsor: Heinrich-Heine University, Duesseldorf
Summary
Robot-assisted image-guided sentinel lymph node biopsy (RAISN) in testicular cancer is a novel technique that has not been widely investigated yet. This technique is promising and could be implemented as a future standard in the primary diagnostic work up of clinical stage (CS) I testicular cancer. Current staging strategies have a poor predictive accuracy for occult metastatic disease. So far, feasibility studies used 99mTC-nanocolloid staining and laparoscopy and all patients with tumor-positive nodes received adjuvant systemic treatment. The development of a robot-assisted image-guided lymph node resection technique with indocyanine green (ICG) is potentially more precise, easier to apply and widely available. With this new diagnostic approach the management of newly diagnosed testicular cancer patients might be changed dramatically by reducing overtreatment and treatment-related toxicity with a minimally invasive robot-assisted procedure.
Official title: RAISN - Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer
Key Details
Gender
MALE
Age Range
18 Years - 99 Years
Study Type
INTERVENTIONAL
Enrollment
44
Start Date
2023-09-06
Completion Date
2028-03-31
Last Updated
2025-09-15
Healthy Volunteers
No
Interventions
Robot-assisted ICG-guided sentinel lymph node biopsy
The robot-assisted ICG-guided sentinel node (SN) biopsy is conducted as follows: At the start of the operation, indocyanine green (ICG) solution is transscrotally injected into the testicular parenchyma. The patient is positioned in the nephrectomy posture. After port placement and docking of the robotic system, the sentinel node(s) should be visible with the fluorescence camera. The SN is removed and sent for immediate frozen section biopsy evaluation. The inguinal orchiectomy is performed subsequently until the biopsy results are available. If the biopsy is negative, the procedure concludes. If the biopsy shows viable tumor, indicating clinical stage IIA and the indication for systematic unilateral retroperitoneal lymph node dissection. The patient was informed about the potential expansion of the procedure upon study enrollment. After the procedure, all patients are placed under observation and do not receive adjuvant systemic treatment. The follow-up period extends to 2 years.
Locations (1)
University Hospital of Duesseldorf
Düsseldorf, Germany